(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

"Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs" was originally created and published by Pharmaceutical ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

New research suggests popular weight loss drugs like Ozempic and Wegovy may affect more than just fat, raising questions about muscle strength and organ size after significant weight loss. University ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.